F/TAF + F/TDF + F/TAF Placebo + F/TDF Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pre-Exposure Prophylaxis of HIV-1 Infection
Conditions
Pre-Exposure Prophylaxis of HIV-1 Infection
Trial Timeline
Sep 2, 2016 → Sep 1, 2027
NCT ID
NCT02842086About F/TAF + F/TDF + F/TAF Placebo + F/TDF Placebo
F/TAF + F/TDF + F/TAF Placebo + F/TDF Placebo is a phase 3 stage product being developed by Gilead Sciences for Pre-Exposure Prophylaxis of HIV-1 Infection. The current trial status is active. This product is registered under clinical trial identifier NCT02842086. Target conditions include Pre-Exposure Prophylaxis of HIV-1 Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02842086 | Phase 3 | Active |
Competing Products
7 competing products in Pre-Exposure Prophylaxis of HIV-1 Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Oral Lenacapavir (LEN) + Subcutaneous (SC) Lenacapavir (LEN) + F/TAF + F/TDF + Placebo SC LEN + PTM Oral LEN + PTM F/TAF + PTM F/TDF | Gilead Sciences | Phase 3 | 76 |
| Lenacapavir Tablet + Lenacapavir Injection + Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) | Gilead Sciences | Phase 2 | 51 |
| Oral Lenacapavir (LEN) + F/TDF + Sub-cutaneous (SC) Lenacapavir (LEN) + Placebo SC LEN + PTM F/TDF + PTM Oral LEN + F/TAF (for US participants only) | Gilead Sciences | Phase 3 | 76 |
| Lenacapavir Injection + Lenacapavir Tablet | Gilead Sciences | Phase 3 | 76 |
| Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Gilead Sciences | Phase 2 | 51 |
| Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Gilead Sciences | Phase 2 | 51 |
| Monoclonal antibody JST-010 + Placebo | Evotec | Phase 1 | 28 |